Xbrane Biopharma AB (STU:7XB0) OCF Margin %: -49.01% (As of Mar. 2026)

What is Xbrane Biopharma AB OCF Margin %?

Xbrane Biopharma AB STU:7XB0 62 OCF Margin % is -49.01% as of Mar. 2026. GuruFocus rates STU:7XB0 with a GF Score™ of 62/100 and a GF Value™ of €1.31. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Xbrane Biopharma AB ranks worse than 63.71% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Xbrane Biopharma AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €-0.79 Mil. Xbrane Biopharma AB's Revenue for the three months ended in Mar. 2026 was €1.61 Mil. Therefore, Xbrane Biopharma AB's OCF Margin % for the quarter that ended in Mar. 2026 was -49.01%.

As of today, Xbrane Biopharma AB's current OCF Yield % is -89.78%.

The historical rank and industry rank for Xbrane Biopharma AB's OCF Margin % or its related term are showing as below:

STU:7XB0' s OCF Margin % Range Over the Past 10 Years
Min: -24764.83 Med: -171.03 Max: 41.35
Current: -249.01

During the past 13 years, the highest OCF Margin % of Xbrane Biopharma AB was 41.35%. The lowest was -24764.83%. And the median was -171.03%.

STU:7XB0's OCF Margin % is ranked worse than
63.71% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs STU:7XB0: -249.01

Xbrane Biopharma AB OCF Margin % Related Terms

Xbrane Biopharma AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB OCF Margin % Chart

Xbrane Biopharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-2,050.05

-336.11

-170.30

-90.30

-164.50

Xbrane Biopharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-73.62	-163.04	-489.54	-742.58	-49.01

STU:7XB0 vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's OCF Margin % falls into.

Save Embed

62GF Score

Xbrane Biopharma AB STU:7XB0

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xbrane Biopharma AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Xbrane Biopharma AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-23.037	/	14.004
	=	-164.50 %

Xbrane Biopharma AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-0.789	/	1.61
	=	-49.01 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -49.01% mean?

Xbrane Biopharma AB (STU:7XB0) has a OCF Margin % of -49.01% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Xbrane Biopharma AB and its competitors. According to the industry distribution chart, Xbrane Biopharma AB ranks #611 out of 959 companies in the Biotechnology industry, placing it in the top 63.7%.

Is Xbrane Biopharma AB's OCF Margin % too high?

Xbrane Biopharma AB's current OCF Margin % is -49.01%. Based on the distribution chart, Xbrane Biopharma AB ranks #611 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xbrane Biopharma AB has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.

How does Xbrane Biopharma AB's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Xbrane Biopharma AB ranks #611 out of 959 companies for OCF Margin %. This places Xbrane Biopharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current OCF Margin % is -49.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xbrane Biopharma AB stock overvalued right now?

Xbrane Biopharma AB (STU:7XB0) has a current OCF Margin % of -49.01%. The stock's GF Value™ is €1.31, compared to a current price of €2.18 — trading 66% above its estimated fair value. The current OCF Margin % is -49.01%. Xbrane Biopharma AB's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Xbrane Biopharma AB (STU:7XB0), the current OCF Margin % is -49.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (STU:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €2.18 is trading 66% above its estimated GF Value™ of €1.31.

Key valuation signals for STU:7XB0:

OCF Margin %: -49.01%
GF Value™: €1.31 vs. price of €2.18 (66% above fair value)
GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the STU:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:NICA OSTO:INIT OSTO:ISOFOL OSTO:XINT XSAT:DEX OSTO:ACTI OSTO:ALZCUR OSTO:DMYD B OSTO:ELIC XSAT:ABERA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges XBRANE:Sweden 7XB0:Germany

Address Scheeles vag 5, Solna, SWE, 171 65

Website https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.

62GF Score

Get the complete analysis for STU:7XB0

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18

Price

€1.31

GF Value

View STU:7XB0 Analysis

See OCF Margin % data for all stocks →